1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PHARMAROTH LABS INC

PHARMAROTH LABS INC

OOTC:ROTH
0.00
USD
0.00
(0.00%)
0.00EPS
5.97MMarket Cap
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
Basic Weighted Avg Shares
26
128
47
131
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-167.58
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-296.65
Working Capital
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
133
133
149
Market Capitalization
8
4
6

Working Capital

USD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
1,185.3%
Free Cash Flow
- -
- -
719.14%
Net Income, GAAP
- -
- -
1,950.61%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
-0.01
2011
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Luis Manuel Ornelas Lopez
Full Time Employees
- -
Sector
Health technology
Industry
Pharmaceuticals: major
Address
8250 West Charleston Boulevard Las Vegas NV United States 89117
IPO Date
Sep 8, 2008
Website
pharmaroth.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
PharmaRoth Labs, Inc. (ROTH) operates as a nutraceutical company focused on the prevention and treatment of type II diabetes worldwide; it produces, markets, and distributes Sucanon, a clinically-tested herbal-based nutraceutical treatment that functions as an insulin sensitizer to improve the body's utilization of insulin and normalize blood sugar levels without risking hypoglycemia. Founded in 2000 and headquartered at 8250 West Charleston Boulevard, Suite 120, Las Vegas, Nevada, the company holds intellectual property rights for Sucanon's production, marketing, and global distribution; it targets consumers managing type II diabetes through oral herbal therapies in the health technology and personal care products sectors. Formerly known as Fero Industries, Inc., the company changed its name to PharmaRoth Labs, Inc. in March 2013, marking its strategic shift to nutraceutical diabetes solutions; no major acquisitions, partnerships, funding rounds, or new product launches have been reported in the last 1-2 years, with recent financials reflecting modest revenue of approximately US$200,000 and ongoing operations under CEO Luis Manuel Lopez.